• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Exagen Inc.

    4/30/25 6:17:09 AM ET
    $XGN
    Medical Specialities
    Health Care
    Get the next $XGN alert in real time by email
    DEFA14A 1 d892240ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    Exagen Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


     

    LOGO

     

    P.O. BOX 8016, CARY, NC 27512-9903

     

    LOGO

       LOGO
     

     

    LOGO

     

      

     

    Meeting Materials: Notice of Meeting, Proxy Statement & 2024 Annual Report on Form 10-K

     

    Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 10, 2025 For Stockholders of record as of April 15, 2025

     

     

    Exagen Inc.

     

    2025 Annual Meeting of Stockholders

    Tuesday, June 10, 2025 9:00 AM, Pacific Time    To order paper materials, use one of the following methods.

    Exagen Administrative Offices, Training Room, 2175 Salk Avenue, 3rd Floor, Carlsbad, California 92008

      

     

      LOGO

     

    For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/XGN.

     

    To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

     

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.

     

    If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before May 27, 2025.

      

    Internet:

    www.investorelections.com/XGN

     

        LOGO

     

    Call:

    1-866-648-8133

     

       LOGO

     

    Email:

    [email protected]

     

    * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

     

    LOGO

         

     

     

    Have the 12 digit control number located in the box above available when you access the website and follow the instructions.

    SEE REVERSE FOR FULL AGENDA

    Copyright © BetaNXT, Inc. or its affiliates. All Rights Reserved    


    LOGO

     

      

    Exagen Inc. 2025 Annual Meeting of Stockholders

      

    THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

    FOR ALL THE DIRECTOR NOMINEES IN PROPOSAL 1, FOR PROPOSAL 2, FOR PROPOSAL 3 AND FOR THE OPTION OF 1 YEAR ON PROPOSAL 4.

     

       PROPOSAL
    1.    To elect two directors to serve as Class III directors for a three-year term expiring at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
      
       1.01 John Aballi
      
       1.02 Bruce C. Robertson, Ph.D.
      
    2.    To ratify the appointment of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
    3.    To approve by an advisory vote the compensation of our named executive officers, as disclosed in the proxy statement; and
    4.    To approve by an advisory vote the frequency of holding an advisory vote on compensation of our named executive officers.
    To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.
    Get the next $XGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XGN

    DatePrice TargetRatingAnalyst
    9/11/2025$15.00Buy
    B. Riley Securities
    7/30/2025$12.00Sector Weight → Overweight
    KeyBanc Capital Markets
    7/23/2025$12.00Buy
    Craig Hallum
    8/5/2022Overweight → Sector Weight
    KeyBanc Capital Markets
    11/11/2021$33.00 → $30.00Overweight
    Keybanc
    10/15/2021$26.00Outperform
    Cowen
    More analyst ratings

    $XGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Exagen with a new price target

    B. Riley Securities initiated coverage of Exagen with a rating of Buy and set a new price target of $15.00

    9/11/25 8:42:21 AM ET
    $XGN
    Medical Specialities
    Health Care

    Exagen upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Exagen from Sector Weight to Overweight and set a new price target of $12.00

    7/30/25 7:17:58 AM ET
    $XGN
    Medical Specialities
    Health Care

    Craig Hallum initiated coverage on Exagen with a new price target

    Craig Hallum initiated coverage of Exagen with a rating of Buy and set a new price target of $12.00

    7/23/25 7:55:19 AM ET
    $XGN
    Medical Specialities
    Health Care

    $XGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Black Jeffrey G. bought $66,448 worth of shares (22,298 units at $2.98), increasing direct ownership by 9% to 274,492 units (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    11/19/24 7:24:38 PM ET
    $XGN
    Medical Specialities
    Health Care

    President and CEO Aballi John bought $68,297 worth of shares (24,305 units at $2.81), increasing direct ownership by 4% to 689,799 units (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    11/18/24 6:32:33 PM ET
    $XGN
    Medical Specialities
    Health Care

    Aballi John bought $77,570 worth of shares (40,401 units at $1.92) (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    5/16/24 8:02:50 PM ET
    $XGN
    Medical Specialities
    Health Care

    $XGN
    SEC Filings

    View All

    Exagen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - EXAGEN INC. (0001274737) (Filer)

    1/12/26 9:03:37 AM ET
    $XGN
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Exagen Inc.

    10-Q - EXAGEN INC. (0001274737) (Filer)

    11/4/25 9:16:21 AM ET
    $XGN
    Medical Specialities
    Health Care

    Exagen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - EXAGEN INC. (0001274737) (Filer)

    11/4/25 8:03:27 AM ET
    $XGN
    Medical Specialities
    Health Care

    $XGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Exagen Inc. Announces Select Preliminary 2025 Financial Results

    CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance. Select Preliminary Unaudited 2025 Results  Revenue  Three Months EndedDecember 31, 2025 Twelve Months EndedDecember 31, 2025Total Revenue$16M to $17M $66M to $67MYear-Over-Year Growth17% to 24% 19% to 20%  Other  Twelve Months EndedDecember 31, 2025AVISE CTD Volume136,000 to 137,000AVISE CTD Trailing 12-month (TTM) average selling price$441 to $445Year-end cash and cash equivalents$32M   The select preliminary una

    1/11/26 3:00:00 PM ET
    $XGN
    Medical Specialities
    Health Care

    Exagen Inc. to Participate in Fourth Quarter Investor Conferences

    CARLSBAD, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences: 16th Annual Craig-Hallum Alpha Select Conference Date: November 18, 2025 Location: Sheraton New York Times Square Hotel Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Date: November 20, 2025 Location: Westin NY Grand Central - 212 E 42nd Street New York, NY 10017 About Exagen Inc. Exagen Inc. (NASDAQ:XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune cond

    11/11/25 9:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    Exagen Inc. Reports Strong Q3 2025 Results

    CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates.   Three Months Ended September 30, Nine Months Ended September 30,  2025 2024 2025 2024(Unaudited, in thousands, except ASP data)  Revenue $17,244  $12,507  $49,944  $41,986 Gross margin  58.4%  55.8%  59.3%  58.7%Operating expenses $13,175  $11,644  $38,688  $34,888 Operating loss $(3,100) $(4,663) $(9,095) $(10,253)Net loss $(7,087) $(5,028) $(15,278) $(11,354)Adjusted EBITDA $(1,895) $(4,024) $(6,124) $(7,614)Cash and cash equivalents $35,652  $22,035  $35

    11/4/25 8:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    $XGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Aballi John sold $375,598 worth of shares (31,787 units at $11.82), decreasing direct ownership by 4% to 714,427 units (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    10/20/25 5:20:07 PM ET
    $XGN
    Medical Specialities
    Health Care

    Chief Financial Officer Black Jeffrey G. sold $200,362 worth of shares (20,466 units at $9.79), decreasing direct ownership by 7% to 269,026 units (SEC Form 4)

    4 - EXAGEN INC. (0001274737) (Issuer)

    9/4/25 7:40:39 PM ET
    $XGN
    Medical Specialities
    Health Care

    Amendment: SEC Form 4 filed by Director Kim Paul

    4/A - EXAGEN INC. (0001274737) (Issuer)

    6/12/25 8:32:07 PM ET
    $XGN
    Medical Specialities
    Health Care

    $XGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Exagen Inc.

    SC 13G/A - EXAGEN INC. (0001274737) (Subject)

    12/12/24 5:00:54 PM ET
    $XGN
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Exagen Inc. (Amendment)

    SC 13G/A - EXAGEN INC. (0001274737) (Subject)

    2/14/24 2:42:55 PM ET
    $XGN
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Exagen Inc. (Amendment)

    SC 13G/A - EXAGEN INC. (0001274737) (Subject)

    2/14/24 7:12:55 AM ET
    $XGN
    Medical Specialities
    Health Care

    $XGN
    Leadership Updates

    Live Leadership Updates

    View All

    Exagen Inc. Appoints Chas McKhann to Board of Directors

    CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Board member, President and CEO of Silk Road Medical, and prior to that, Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific, resulting in significant shareholde

    7/17/25 4:05:00 PM ET
    $XGN
    Medical Specialities
    Health Care

    Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

    CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany. During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune resea

    6/23/25 9:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

    CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. "I sincerely thank Kamal for his leadership and numerous contributions to Exagen over the past decade," said John Aballi, President and CEO of Exagen. "Kamal has been extremely supportive throughout my time with the Company, and I am very appreciative of his dedication to our customers and organization. I appreci

    8/1/24 9:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    $XGN
    Financials

    Live finance-specific insights

    View All

    Exagen Inc. Reports Strong Q3 2025 Results

    CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates.   Three Months Ended September 30, Nine Months Ended September 30,  2025 2024 2025 2024(Unaudited, in thousands, except ASP data)  Revenue $17,244  $12,507  $49,944  $41,986 Gross margin  58.4%  55.8%  59.3%  58.7%Operating expenses $13,175  $11,644  $38,688  $34,888 Operating loss $(3,100) $(4,663) $(9,095) $(10,253)Net loss $(7,087) $(5,028) $(15,278) $(11,354)Adjusted EBITDA $(1,895) $(4,024) $(6,124) $(7,614)Cash and cash equivalents $35,652  $22,035  $35

    11/4/25 8:00:00 AM ET
    $XGN
    Medical Specialities
    Health Care

    Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025

    CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesday, November 4, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast: U.S. dial-in: 201-389-0918International dial-in: 877-407-0890Webcast: Available via the Exagen investor relations website at investors.exagen.com Replay: A telephone replay will be available until Tuesday, November 1

    10/21/25 4:05:00 PM ET
    $XGN
    Medical Specialities
    Health Care

    Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

    CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, July 29, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exa

    7/15/25 4:05:00 PM ET
    $XGN
    Medical Specialities
    Health Care